Curevo Vaccine

Acquired

Creating Better Vaccines

Bothell, United States · Founded 2017 · $196.0M raised

Employees
11–50
Founded
2017
Business Model
B2B
Total Funding
$196.0M
Last Round
$110.0M Series BMar 2025
Rounds
3
Acquisition Date
May 2026

About

Curevo Vaccine is a clinical-stage biotechnology company founded in 2017 and headquartered in Bothell, Washington. It develops next-generation non-mRNA adjuvanted subunit vaccines targeting unmet medical needs, with its lead program amezosvatein (CRV-101) advancing through Phase 2 clinical trials for shingles and chickenpox with superior tolerability versus Shingrix.

Summary

Curevo Vaccine is a Biotech company based in Bothell, United States, founded in 2017. It has raised $196.0M in total across 3 rounds, most recently a $110.0M Series B round in Mar 2025. Investors include Janus Henderson Investors, Eli Lilly and Medicxi.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

AcquisitionMay 2026
$1.5B

Sign up to see all 4 rounds

Series A through Acquisition — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Curevo Vaccine on Indexed.vc
<a href="https://indexed.vc/companies/curevo-vaccine"><img src="https://indexed.vc/api/badge/company/curevo-vaccine" alt="Curevo Vaccine on Indexed.vc" width="260" height="76" /></a>